ATYPICAL RESPONDERS LANDSCAPE REVIEW ∙ OCTOBER, 2017 31 TABLE 1 CATEGORIES AND TERMS RELATED TO ATYPICAL RESPONDERS STUDYOR INSTITUTE QUALITATIVEDEFINITION METRICS/QUANTITATIVECRITERIA NCI Study: Molecular ProfilinginTissue SamplesFrom PatientsWith CancerWho Are Exceptional Respondersto Treatment “Exceptionalresponders”arepatients who haveauniqueresponsetotreatmentsthat are noteffectiveformostotherpatients. •Completeresponsetotreatment expectedin 6monthsexpectedin10 years,OR •Duration on anyonetherapy(progression-freesurvival;PFS),>3years Forpatients withtriple negative MBC (TNBC): •Duration with metastaticdisease(overall survival),>5years,OR •Duration on anyonetherapy(PFS), >2 years OR,foreithergroup: •Anycompleteresponse, ornearcomplete, toanytherapy(forany length oftime) •Anyotherclinical scenariothat theinvestigatorsbelieve constitutes an extraordinaryresponse/outcome (Thestudydoesnot definerapidprogressors) AURORA(Aiming toUnderstand theMolecular Aberrations inMetastatic Breast Cancer) Defines“exceptionalresponders”asthose “showing(nearly)completeresponsefor adurationexceeding1year”and“rapid progressors”as“patientsonfirst-orsecond- linetreatmentprogressingwithinthefirst 3 monthssinceitsinitiation”[5]. •Exceptional Responders: Completeresponseforadurationof ≥1year •RapidProgressors: Progressedwithin